Cardioverter-defibrillators and sudden cardiac death prevention: Clinical and economic implications of the MADIT II study;Defibrillatori impiantabili e prevenzione della morte improvvisa: Implicazioni cliniche ed economiche alla luce dello studio MADIT II

Monaldi Archives for Chest Disease

Volumn 58, Issue 2, 2002, Pages 145-150

  Boriani, G ^a   Biffi, M ^a   Martignani, C ^a   Branzi, A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Implantable cardioverter defibrillator; Sudden cardiac death; Ventricular tachyarrhytmia

Indexed keywords

CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATION; DEFIBRILLATOR; DEVICE; DYNAMICS; HEALTH CARE COST; HEALTH ECONOMICS; HEART DEATH; HEART ELECTROPHYSIOLOGY; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; MARKETING; MORTALITY; PATIENT SELECTION; REVIEW; RISK ASSESSMENT; SUDDEN DEATH; COST BENEFIT ANALYSIS; ECONOMICS;

CLINICAL TRIALS; COST-BENEFIT ANALYSIS; DEATH, SUDDEN; DEFIBRILLATORS, IMPLANTABLE; HUMANS;

EID: 0036719698     PISSN: 11220643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Camm AJ, Nisam S. - The utilization of the implantable defibrillator - A European enigma. Eur Heart J 2000; 21: 1998-2004.
2. Wilber DJ, Koll JG, Kapp DE. - What can we expect from prophylactic implantable cardioverter defibrillators? Am J Cardiol 1997; 80 (suppl. 5B): 20F-27F.
3. Domanski MJ, Zipes DP, Schron E. - Treatment of sudden cardiac death. Circulation 1997; 95: 2694-2699.
4. Bigger JT, Fleiss JL, Kleiger L, et al. - The relationship among ventricular arrhythmias, left ventricular dysfunction and mortality in the 2 years after myocardial infarction. Am J Cardiol 1986; 69: 250-258.
5. Buxton AE, Lee KL, Fisher JD, et al. - A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial investigators. N Engl J Med 1999; 341 (25): 1882-1890.
6. Maggioni AP, Zuanetti G, Franzosi MG, et al. - Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era: GISSI-2 results. Circulation 1993; 87: 312-322.
7. Moss AJ, Hall J, Cannom DS, et al. - Improved survival with an implantable defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335: 1933-1940.
8. Moss AJ, Zareba W, Hall WJ, et al. - Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-883.
9. Bigger JT. - Expanding indications for implantable cardiac defibrillators. N Engl J Med 2002; 346: 931-3.
10. Gregoratos G, Cheitlin MD, Conill A, et al. - ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation). J Am Coll Cardiol 1998; 31: 1175-209.
11. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. - Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 2001; 16: 1374-1450.
12. Ruskin JN, Camm AJ, Zipes DP, et al. - Implantable cardioverter defibrillator utilization based on discharge diagnoses from Medicare and managed care patients. J Cardiovasc Electrophysiol 2002; 13: 38-43.
13. Pathmanarthan RK, Lau EW, Cooper J, et al. - Potential impact of Antiarrhythmic drugs versus implantable defibrillators on the management of ventricular arrhythmias: The Midlands trial of empirical amiodarone versus electrophysiologically guided intervention and cardioverter implant registry data. Heart 1998; 80: 68-70.
14. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med 1997; 337: 1576-83.
15. Goldman L, Gordon DG, Rifkind BM, et al. - Cost and health implications of cholesterol lowering. Circulation 1992; 85: 1960-1968.
16. Kupersmith J, Holmes-Rovner M, Rovner D, et al. - Cost-effectiveness analysis in heart disease. Part II. Preventive therapies. Progress in Cardiovascular Diseases 1995; 37: 243-271.
17. Kupersmith J, Holmes-Rovner M, Rovner D, et al. - Cost-effectiveness analysis in heart disease. Part III. Ischemia, congestive heart failure and arrhythmias. Progress in Cardiovascular Diseases 1995; 37: 307-346.
18. Kupersmith J. - Cost-effective strategies in cardiology. In: Hurst JW et al. The Heart. Arteries and Veins. 9th Edition. New York: Mc Graw Hill, 1998: 2557-2578.
19. Boriani G, Biffi M, Martignani C, et al. - Cost-effectiveness of implantable cardioverter-defibrillators. Eur Heart J 2001; 22: 990-996.
20. Van Hout BA, Simoons ML. - Cost-effectiveness of HMG coenzyme reductase inhibitors; Whom to treat? Eur Heart J 2001; 22: 751-61.
21. Malik IS, Bhatia VK, Kooner JS. - Cost effectiveness of ramipril treatment for cardiovascular risk reduction. Heart 2001; 85: 539-543.
22. Saksena S, Madan N, Lewis C. - Implanted cardioverter defibrillators are preferable to drugs as primary therapy in sustained ventricular tachyarrhythmias. Progress in Cardiovascular Diseases 1996; 38: 445-454.
23. Kupersmith J, Hogan A, Guerrero P, et al. - Evaluating and improving the cost-effectiveness of the implantable cardioverter-defibrillator. Am Heart J 1995; 130: 507-515.
24. Larsen GC, Manolis AS, Sonnenberg FA, et al. - Cost-effectiveness of the implantable cardioverter defibrillator: Effect of improved battery life and comparison with amiodarone therapy. J Am Coll Cardiol 1992; 19: 1323-1334.
25. Owens DK, Sanders GD, Harris RA, et al. - Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. Ann Intern Med 1997; 126: 1-12.
26. Larsen GC, McAnulty JH, Hallstrom A, et al. - Hospitalization charges in the antiarrythmics versus implantable defibrillators (AVID) trial: The AVID economic analysis study (Abstr). Circulation 1997; 96 (Suppl 8): I-77.
27. Sheldon R, O'Brien BJ, Blackhouse G, et al. - Effect of clinical risk stratification on cost-effectiveness of the implantable cardioverter-defibrillator: The Canadian implantable defibrillator study. Circulation 2001; 104: 1622-1626.
28. Hlatky MA, Bigger T. - Cost-effectiveness of the implantable cardioverter defibrillator? Lancet 2001; 357: 1817-1818.
29. Botto GL. - Comunicazione Congresso AIAC Aprile 2002, Bologna, Italia.
30. Sanders GD, Hlatky MA, Every NR, et al. - Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. Ann Intern Med 2001; 135: 870-83.
31. Zareba W. - Late breaking clinical trials: Noninvasive Electrocardiology and Outcome in MADIT II Patients. NASPE 2002, 23rd Scientific Session, San Diego May 8-11, 2002. www.naspe.org.
32. Zipes DP. - Implantable Cardioverter-Defibrillator: A Volkswagen or a Rolls Royce: How much will we pay to save a life? Circulation 2001; 103: 137-1374.